Study data convince Lundbeck to push new migraine drug forward

A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.

Raccontata dabiopharmadive.com